Logo for Diagonal Bio

Diagonal Bio Investor Relations Material

Latest events

Logo for Diagonal Bio

Q3 2023

31 Oct, 2023
Logo for Diagonal Bio

Q2 2023

22 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.